Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.710
-0.016 (-2.20%)
At close: Feb 21, 2025, 4:00 PM
0.715
+0.005 (0.70%)
After-hours: Feb 21, 2025, 7:50 PM EST
Lexicon Pharmaceuticals Stock Forecast
LXRX's stock price has decreased by -73.21% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Lexicon Pharmaceuticals stock has a target of 4.00, which predicts an increase of 463.38% from the current stock price of 0.71.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Lexicon Pharmaceuticals stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +463.38% | Jan 29, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 29, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 23, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 25, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 22, 2024 |
Financial Forecast
Revenue This Year
11.35M
from 1.20M
Increased by 842.94%
Revenue Next Year
13.60M
from 11.35M
Increased by 19.76%
EPS This Year
-0.70
from -0.80
EPS Next Year
-0.48
from -0.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 32.9M | 40.0M | 88.3M | |||
| Avg | 11.4M | 13.6M | 27.5M | |||
| Low | 6.4M | 4.8M | 3.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2,629.7% | 252.2% | 549.6% | |||
| Avg | 842.9% | 19.8% | 102.0% | |||
| Low | 429.1% | -57.7% | -77.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.64 | -0.33 | -0.26 | |||
| Avg | -0.70 | -0.48 | -0.42 | |||
| Low | -0.75 | -0.64 | -0.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.